Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this report, four cases of noncicatricial alopecia developed following a single session of dutasteride mesotherapy in patients with androgenetic alopecia, highlighting potential adverse effects and the need for careful monitoring of the drug's composition.

Dutasteride and finasteride do not increase mood disorder risk in men with hair loss.

This study found that long-term use of dutasteride in men taking it for androgenetic alopecia may lead to persistent decreases in semen volume and sperm motility, potentially impacting fertility, with significant impairment observed after 17.8 to 20.3 months of treatment.

Five monthly sessions of minoxidil-dutasteride-copper peptide tattooing significantly improve hair regrowth in men with androgenetic alopecia.

Low-dose oral minoxidil alone is effective for treating hair loss, but combining it with dutasteride or finasteride may offer better results.

This review discusses the pharmacokinetics, pharmacodynamics, efficacy, and side effects of dutasteride for androgenetic alopecia, reporting that it may be more effective than finasteride, though potential impacts on male fertility need consideration when prescribing.

In this study, researchers found that combining fractional CO2 laser sessions with topical dutasteride was more effective in improving male androgenic alopecia than using the laser treatment alone, as observed through global photo assessments and dermoscopic parameters.

This review examines recent advancements in analytical techniques used to quantify dutasteride, a medication for enlarged prostate, in various biological samples and its commercial forms, emphasizing methods such as HPTLC, GC-MS, and HPLC.

This pilot study found that using skin patting and iontophoresis to deliver a 6% dutasteride gel led to significant improvements in hair density and shaft diameter in men and postmenopausal women with treatment-resistant androgenetic alopecia, with no reported adverse events.

In this study, 0.2 mg dutasteride significantly improved hair growth in men with androgenetic alopecia compared to placebo over 24 weeks, showing similar efficacy to the higher 0.5 mg dose with a favorable safety profile.

Dutasteride may become the top choice for treating hair loss.

This study reports that a novel Nano-Structured Lipid Carrier system for delivering dutasteride may enhance its anticancer effects while reducing systemic side effects in clinical settings.

In this study, researchers developed and evaluated a topical dutasteride gel for treating male pattern baldness, finding that a formulation with 10% garlic extract showed the most promising results in promoting faster hair growth compared to other formulations tested.

In this retrospective cohort study, researchers found no significant difference between finasteride and dutasteride in terms of reducing prostate volume or adverse effects among patients with benign prostatic hyperplasia, although both drugs improved lower urinary tract symptoms over one year by reducing prostate volume.

This study found that a topical gel formulation containing Dutasteride-loaded niosomes was stable for 90 days and facilitated improved drug release, suggesting potential for enhanced bioavailability in topical applications.

This review discusses the current therapies for androgenic alopecia, emphasizing topical formulations like minoxidil and finasteride and exploring the potential of dutasteride-loaded nanocarriers for targeting hair follicles to minimize systemic side effects from oral treatment.

This study found that dutasteride-loaded transfersomes, compared to traditional liposomes, better target hair follicles by releasing the drug in a more controlled manner, as shown in vitro with enhanced follicular targeting (Tf = 0.32 versus 0.15, p < 0.005) using porcine ear skin.

This study formulated and characterized a dutasteride-loaded nanocrystalline suspension for long-acting parenteral delivery, finding that it provided sustained drug release in rats with a significant reduction in local inflammation over 28 days following intramuscular injection.

In this retrospective analysis, dutasteride mesotherapy was used in 10 patients with androgenetic alopecia and resulted in hair density and width changes measured at the scalp, but specific efficacy results are not detailed in the abstract.

In this study, researchers assessed the physical-chemical and microbiological stability of various pharmaceutical ingredients in the vehicle TrichoSolTM, finding differing beyond-use dates for the compounds, such as 180 days for cetirizine hydrochloride, but only 90 days for progesterone at higher concentrations.

In this study, among 30 patients with androgenetic alopecia, topical Minoxidil was effective alone or in combination with either oral or microneedling-applied Dutasteride, with the microneedling approach offering promising results and fewer side effects compared to oral Dutasteride.

Finasteride and dutasteride can increase beard thickness in men.

Both treatment combinations improved hair growth similarly and were safe.

This abstract discusses finasteride and dutasteride's mechanisms in treating androgenetic alopecia and notes FDA approval for finasteride, but reports no new clinical results.

In this clinical trial, 16 women with frontal fibrosing alopecia experienced significant improvements in hair density, vellus hair count, and quality of life after monthly intralesional dutasteride treatments, though larger and longer-term studies are needed to confirm these findings.

Finasteride and dutasteride do not significantly change beard thickness in men.

This study established a new reverse-phase high-performance liquid chromatography method to accurately and precisely quantify silodosin and dutasteride in mixtures, meeting International Council of Harmonization validation criteria for stability, sensitivity, and recovery.

This study developed a topical dutasteride-loaded Insitu-emulgel for treating androgenetic alopecia, finding it effectively controls drug release, enhances skin penetration, and may improve patient compliance compared to traditional topical treatments, though further clinical research is underway.

In this study, dutasteride was found to be effective and safe in treating androgenetic alopecia in men who did not respond to finasteride, with improvements observed in hair loss and quality over 24 weeks.

This article discusses how 5-alpha-reductase inhibitors like finasteride and dutasteride are used to treat androgenetic alopecia, while highlighting the ongoing debate over their potential side effects, including sexual dysfunction and psychological issues.